1,916 material Form 8-K filings that 1,609 companies we cover made with the SEC in July 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Gaming and Leisure Properties reported second-quarter 2026 total revenue of $430.5 million, up from $394.9 million a year earlier, and net income of $234.9 million, or $0.80 per diluted share, versus $156.2 million and $0.54. The company raised the midpoint of its 2026 AFFO per share guidance to $4.10 to $4.12 and raised its quarterly dividend to $0.82 from $0.78, which matters to shareholders because it reflects higher reported earnings and cash flow measures.
Q2 2026 total revenue $430.5 million vs. $394.9 million in Q2 2025
Q2 2026 net income $234.9 million; diluted EPS $0.80 vs. $0.54
2026 AFFO per diluted share guidance now $4.10 to $4.12, vs. prior $4.08 to $4.12
Quarterly dividend raised to $0.82 per share from $0.78
Greif reported fiscal third-quarter 2026 results for the period ended June 30, 2026, with net income up 156.7% year over year and adjusted EBITDA up 24.7% to $183.4 million. The company also raised its quarterly dividend by 10.7%, cut net debt by $1,689.9 million to $741.9 million, and said it will begin executing share repurchases under a new plan.
Net income of $78.8 million, or $1.37 per diluted Class A share, versus $30.7 million, or $0.53, a year earlier
Adjusted EBITDA of $183.4 million, up 24.7% from $147.1 million; net sales of $1,165.6 million, up from $1,125.9 million
Fiscal 2026 Adjusted EBITDA outlook of $615 million to $635 million and Adjusted free cash flow outlook of $305 million to $325 million
Moog reported fiscal third-quarter 2026 results for the quarter ended June 27, 2026, with net sales up 15% to $1.1 billion and GAAP diluted earnings per share of $4.74, compared with $1.83 a year earlier. The company raised its fiscal 2026 guidance for net sales, adjusted operating margin, adjusted diluted earnings per share and free cash flow conversion, and its Board declared a $0.30 quarterly dividend. Results were helped by $30 million of claims related to previously incurred IEEPA tariffs and by income tax benefits, and the filing notes that the quarter's figures reflect the correction of immaterial prior-period misstatements.
Net sales were $1.1 billion, up 15% from $970 million in the third quarter of 2025; GAAP diluted EPS was $4.74 versus $1.83.
Adjusted diluted EPS was $3.72 versus $2.33, and operating margin was 15.8% versus 11.5%.
Fiscal 2026 guidance raised: net sales to $4.4 billion from $4.3 billion; adjusted diluted EPS to $11.65 from $10.60.
Quarterly dividend of $0.30 per share is payable August 25, 2026, to holders of record as of August 14, 2026.
IES Holdings reported fiscal third-quarter revenue of $1,242.7 million, up 40% from a year earlier, and net income attributable to the company of $153.0 million, up 98%. The board also approved a two-for-one forward stock split, with shares distributed after the close of trading on August 21, 2026 to holders of record on August 14, 2026.
Revenue of $1,242.7 million vs. $890.2 million a year earlier; diluted EPS of $7.57 vs. $3.81
Net income attributable to IES of $153.0 million vs. $77.2 million, including a $26.2 million gain on marketable securities
Residential segment revenue fell 6% to $324.1 million and operating income fell to $16.3 million from $33.4 million
Two-for-one stock split: record date August 14, 2026; one additional share per share held, distributed after the close on August 21, 2026
CubeSmart reported second-quarter 2026 results, with diluted EPS rising to $0.39 from $0.36 a year earlier while FFO, as adjusted, per diluted share fell 3.1% to $0.63. The company said the midpoints of its same-store revenue, same-store NOI and FFO guidance ranges increased, and it set 2026 EPS guidance of $1.58 to $1.64 and FFO, as adjusted, per share guidance of $2.54 to $2.60. The company also agreed to form a Heitman joint venture for 15 stores valued at $197.0 million, expected to close in the fourth quarter of 2026.
Q2 2026 total revenues rose to $286.5 million from $282.3 million, and same-store NOI fell 0.7% year over year
Diluted EPS was $0.39 versus $0.36; FFO, as adjusted, totaled $143.1 million versus $148.9 million
2026 guidance: diluted EPS of $1.58 to $1.64 and FFO, as adjusted, per diluted share of $2.54 to $2.60
Repurchased 1.1 million shares for $42.5 million; revolving credit facility increased from $850 million to $1 billion and extended to June 2030
Gates Industrial Corporation reported second-quarter 2026 net sales of $941.6 million, up 6.6% from a year earlier, and net income attributable to shareholders of $170.9 million, or $0.67 per diluted share, compared with $56.5 million, or $0.22, in the prior-year quarter. The company raised its full-year 2026 guidance for core sales growth, adjusted EBITDA and adjusted earnings per share, which matters to shareholders because it signals higher expected profitability for the year.
Second-quarter net sales were $941.6 million, up 6.6%, with core sales up 4.9%.
Net income attributable to shareholders was $170.9 million, or $0.67 per diluted share, versus $56.5 million, or $0.22, a year earlier; the quarter included an income tax benefit of $78.0 million.
Adjusted net income per diluted share was $0.44, up from $0.39 a year earlier.
Updated 2026 guidance: adjusted EBITDA of $800 million to $830 million (previously $775 million to $835 million) and adjusted EPS of $1.62 to $1.70 (previously $1.52 to $1.68).
Cboe reported second-quarter 2026 net revenue of $731.6 million, up 25% from a year earlier, and diluted EPS of $3.35, up 50%. It raised its 2026 organic total net revenue growth target to 'mid to high teens', which signals higher expected growth for shareholders, while cutting 2026 adjusted operating expense guidance by $11 million tied to the expected third-quarter sale of Cboe Australia.
Net revenue of $731.6 million, up 25%; Options net revenue of $473.9 million, up 30%
Diluted EPS of $3.35, up 50%; adjusted diluted EPS of $3.56, up 45%
2026 organic total net revenue growth target raised to 'mid to high teens' from 'low double-digit to mid teens'
2026 adjusted operating expense guidance of $838 to $853 million reaffirmed, reduced by $11 million for the expected Cboe Australia sale
Newell Brands reported second quarter 2026 net sales of $2.0 billion, up 3.0% from a year earlier, and its first year-over-year sales growth in over four years, with diluted EPS of $0.25 versus $0.11. The company raised its full-year 2026 outlook for net sales, normalized operating margin, normalized EPS and operating cash flow, though results included about $126 million pretax in IEEPA tariff recoveries.
Q2 net sales were $1,994 million, up 3.0%; core sales rose 2.3%.
Diluted EPS was $0.25 versus $0.11; normalized diluted EPS was $0.42 versus $0.24.
Full-year 2026 normalized EPS outlook raised to $0.73 to $0.77 from $0.56 to $0.60.
Q2 included about $100 million pretax from 2025 IEEPA tariff recoveries, plus about $26 million from Q1 2026 tariff recoveries.
Werewolf Therapeutics reported second quarter 2026 net income of $3.7 million, compared with a net loss of $18.0 million a year earlier, driven by $21.0 million of collaboration revenue tied to the sale of its JZP898 program to Jazz Pharmaceuticals Ireland Limited. Cash and cash equivalents fell to $22.0 million at June 30, 2026, and the company expects to fund operations into the second quarter of 2027, so shareholders should weigh the one-time revenue against the lower cash balance and the ongoing strategic alternatives process.
Net income was $3.7 million for Q2 2026, versus a net loss of $18.0 million in Q2 2025.
Collaboration revenue was $21.0 million in Q2 2026, from the JZP898 asset sale to Jazz; no collaboration revenue was recognized in Q2 2025.
Cash and cash equivalents were $22.0 million at June 30, 2026, down from $46.5 million at March 31, 2026; the company expects to fund operations into Q2 2027.
The company is running a strategic alternatives process with Piper Sandler & Co. and expects updates in the second half of 2026.
Moderna reported second-quarter 2026 revenue of $145 million, up from $142 million a year earlier, and a GAAP net loss of $(0.8) billion, or $(1.97) per share, versus $(2.13) per share in the prior-year quarter. The company improved its 2026 operating expense outlook, lowering R&D to approximately $2.9 billion and projecting year-end cash and investments of $4.7 to $5.2 billion, but its norovirus candidate mRNA-1403 did not meet early-success criteria at a Phase 3 interim analysis.
Q2 2026 revenue $145 million vs $142 million; net loss $(782) million vs $(825) million
Loss per share $(1.97) vs $(2.13) in Q2 2025
2026 R&D now approximately $2.9 billion (from $3.0 billion); cost of sales approximately $1.7 billion (from $1.8 billion), including a $0.9 billion litigation settlement charge
mRNA-1403 norovirus Phase 3 missed interim early-success criteria; mFLUSIVA U.S. PDUFA date is August 5, 2026
Lear reported second-quarter 2026 sales of $6.2 billion, up 3%, and net income attributable to Lear of $193 million, up from $165 million a year earlier. The company also raised the midpoints of its full-year 2026 outlook and narrowed most ranges, which points to higher expected earnings and cash flow for shareholders.
Q2 2026 diluted EPS was $3.79 versus $3.06; adjusted EPS was $4.28 versus $3.47 in Q2 2025.
Core operating earnings were $313 million, up 7% from $292 million, and free cash flow was $288 million versus $171 million.
Full-year 2026 outlook: net sales of $23.54 billion to $24.01 billion and core operating earnings of $1.08 billion to $1.20 billion.
Lear repurchased $100 million of shares in the quarter and had about $600 million of authorization remaining at quarter-end.
nVent reported second-quarter 2026 sales of $1.5 billion, up 53%, and diluted EPS of $1.32, up 103%, with adjusted EPS of $1.45, up 69%. The company raised its full-year 2026 guidance, including adjusted EPS of $5.00 to $5.10, up from $4.45 to $4.55, which signals a higher earnings outlook for shareholders.
Q2 2026 operating income was $301 million, up 92%; adjusted operating income was $323 million, up 61%.
Full-year 2026 reported sales growth guidance is 37% to 39%, up from 26% to 28%.
Full-year 2026 GAAP EPS guidance is $4.29 to $4.39, up from $3.68 to $3.78; adjusted EPS guidance is $5.00 to $5.10, up from $4.45 to $4.55.
Third-quarter 2026 adjusted EPS is estimated at $1.35 to $1.38; a $0.21 quarterly dividend is payable August 7, 2026.
LyondellBasell reported second-quarter 2026 net income of $559 million, or $1.71 per diluted share, up from $125 million, or $0.38, in the first quarter, as higher margins amid Middle East supply disruptions lifted results. The quarter included $842 million of identified items, net of tax, mainly a $734 million pre-tax loss on the May 2026 divestiture of select European olefins and polyolefins assets. The company expects supply conditions to remain volatile and its recovery period to likely extend into 2027, with lower third-quarter operating rates at some assets.
Net income of $559 million ($1.71 per diluted share) versus $125 million ($0.38) in Q1 2026 and $115 million ($0.34) in Q2 2025.
Excluding identified items, net income was $1.4 billion, or $4.30 per diluted share, after a $734 million pre-tax loss on sale of European assets.
Sales and other operating revenues were $9,177 million, up from $7,197 million in Q1 2026 and $7,658 million in Q2 2025.
Third-quarter 2026 operating rates expected at 85% for North American O&P assets, 70% for European O&P assets and 85% for Intermediates & Derivatives assets.
Protolabs reported record second quarter 2026 revenue of $149.3 million, up 10.6% from a year earlier, and GAAP diluted EPS of $0.37 versus $0.18 in the prior-year quarter. The company raised its full-year 2026 revenue growth guidance to 8% to 10%, from 6% to 8%, and gave third-quarter revenue guidance of $145.0 million to $153.0 million.
Q2 2026 revenue was a record $149.3 million, up 10.6% year-over-year; GAAP net income was $9,152 thousand, versus $4,427 thousand a year earlier
Non-GAAP diluted EPS was $0.60 versus $0.41 in Q2 2025; GAAP diluted EPS was $0.37 versus $0.18
Full-year 2026 revenue growth guidance raised to 8% to 10%, from 6% to 8%
Q3 2026 outlook: revenue of $145.0 million to $153.0 million and GAAP diluted EPS of $0.34 to $0.42
BrightSpring reported second quarter 2026 net revenue of $3.87 billion, up 23.0% from a year earlier, and net income of $87 million compared with $9 million in the second quarter of 2025. The company also raised its full-year 2026 revenue and Adjusted EBITDA guidance, which excludes the Community Living business it divested on March 30, 2026. For shareholders, the quarter shows higher revenue and profit and a higher full-year outlook.
Q2 2026 net revenue of $3,873 million, up 23.0% from $3,148 million; gross profit of $493 million, up 31.5%
Net income of $87 million vs. $9 million in Q2 2025; diluted EPS of $0.38 vs. $0.13 attributable to common shareholders
Full-year 2026 revenue guidance raised to $15,100 million to $15,425 million; Adjusted EBITDA guidance raised to $820 million to $845 million
Leverage fell to 2.15x at June 30, 2026, from 2.27x at March 31, 2026, after a $300.0 million First Lien Facility paydown
Forum Energy Technologies reported second quarter 2026 revenue of $226 million, up from $200 million a year earlier, and net income of $12 million, or $1.05 per diluted share, compared with $7.7 million, or $0.61, in the second quarter of 2025. The company raised all of its full year 2026 guidance metrics, including revenue of $870 million to $910 million, which signals stronger expected results for shareholders.
Q2 2026 revenue was $226 million versus $200 million in Q2 2025; orders were $236 million with a 104% book-to-bill ratio
Diluted EPS was $1.05 versus $0.61 a year earlier; adjusted diluted EPS was $1.16 versus a loss of $0.10
Full year 2026 guidance: revenue $870 million to $910 million, adjusted EBITDA $115 million to $125 million, free cash flow $57 million to $77 million
Third quarter 2026 revenue guidance is $225 million to $245 million; net leverage ratio was 1.1 times at June 30, 2026
Mettler-Toledo reported second-quarter 2026 sales of $1.027 billion, up 4% from a year earlier, and diluted EPS of $11.55 versus $9.76. Adjusted EPS was $11.46, up 14%, and the company raised its full-year 2026 adjusted EPS forecast to $47.15-$47.50 from $46.30-$46.95. Results include a one-time net tariff refund benefit that management excludes from its non-GAAP figures.
Q2 2026 reported sales rose 4% to $1.027 billion; local currency sales rose 6% excluding a one-time tariff refund to customers.
Diluted EPS was $11.55 (up from $9.76); adjusted EPS was $11.46 (up 14% from $10.09).
Full-year 2026 adjusted EPS forecast raised to $47.15-$47.50 from $46.30-$46.95; Q3 adjusted EPS forecast is $12.00-$12.15.
Non-GAAP results exclude a one-time $52 million IEEPA tariff refund benefit to cost of sales and a related $28 million refund to customers that reduced net sales.
MasTec reported second quarter 2026 revenue of $4.4 billion, up 23% year over year, with GAAP diluted EPS of $1.65 and adjusted diluted EPS of $2.22, up 51% and 49%. The company raised its full-year 2026 adjusted diluted EPS guidance to $9.30 and set GAAP diluted EPS guidance at $6.20, which matters to shareholders because it signals higher expected profit for the year.
Q2 2026 revenue of $4.37 billion, up 23.4% year over year; GAAP net income of $146 million, up 61.7%
Full-year 2026 adjusted diluted EPS guidance raised to $9.30; GAAP diluted EPS guidance of $6.20; third-quarter revenue estimate of $4.93 billion
18-month backlog of $21.4 billion at June 30, 2026, up $4.9 billion year over year and $1.1 billion from the prior quarter
Board appointed Alexander Benjamin Spiro as a Class III director effective July 24, 2026, expanding the board from nine to ten members
Carpenter Technology reported fiscal fourth quarter 2026 operating income of $206.9 million, up from $151.4 million a year earlier, and diluted earnings per share of $3.23, up from $2.21. For fiscal 2027, the company expects operating income of $850 million to $880 million and adjusted free cash flow of $400 million to $430 million, and it set a fiscal 2029 operating income target of $1.2 billion to $1.3 billion.
Q4 fiscal 2026 net sales were $851.0 million, up from $755.6 million, and diluted EPS was $3.23 versus $2.21.
Fiscal 2026 operating income was $702.0 million, up from $521.8 million, and diluted EPS was $10.52 versus $7.42.
Fiscal 2027 outlook: operating income of $850 million to $880 million and adjusted free cash flow of $400 million to $430 million.
Q4 share repurchases totaled $45.2 million; $119.0 million remained available under the $400.0 million program as of June 30, 2026.
Cousins Properties reported second-quarter 2026 net income available to common stockholders of $26.2 million, or $0.16 per share, up from $14.5 million a year earlier, mainly due to a gain on the sale of an investment property. Funds from operations (FFO) rose to $124.6 million, or $0.75 per share, and the company raised its 2026 net income and FFO per share guidance, which matters to shareholders because it signals higher expected earnings for the year, though first-half net income fell sharply due to an impairment charge.
Q2 2026 net income available to common stockholders was $26.2 million, or $0.16 per share, compared with $14.5 million, or $0.09 per share, in Q2 2025.
Q2 2026 FFO was $124.6 million, or $0.75 per share, compared with $117.5 million, or $0.70 per share, in Q2 2025.
2026 FFO guidance is now $2.92 to $2.98 per share, up from $2.90 to $2.98; net income guidance is $0.08 to $0.14 per share, up from $0.02 to $0.10.
Six-month 2026 net income available to common stockholders fell to $1.3 million, or $0.01 per share, from $35.4 million, mainly due to a $36.6 million operating property impairment.
Veracyte reported second-quarter 2026 total revenue of $150.3 million, up 15% from a year earlier, and GAAP net income of $25.5 million, or $0.31 per diluted share, compared with a net loss of $980,000 a year earlier. The company raised its 2026 total revenue guidance to $590 million to $596 million, which signals stronger expected growth for shareholders.
Total revenue rose 15% to $150.3 million; testing revenue rose 19% to $145.7 million
GAAP net income was $25.5 million, or $0.31 per diluted share, versus a net loss of $980,000 in Q2 2025
2026 total revenue guidance raised to $590 million to $596 million from $582 million to $592 million
Cash, cash equivalents and short-term investments totaled $485.2 million as of June 30, 2026
Eastman reported second-quarter 2026 sales of $2,513 million, up 10% from $2,287 million a year earlier, with GAAP diluted EPS of $1.59 versus $1.20 and adjusted EPS of $1.97 versus $1.60. The company now expects 2026 operating cash flow to approach $900 million, modestly below its prior expectation of approaching 2025 levels, and projects third-quarter adjusted EPS to approach the $1.97 second-quarter level.
Second-quarter sales rose 10% to $2,513 million; Chemical Intermediates sales rose 39% while Fibers fell 11%
Adjusted EBIT rose to $320 million from $275 million; GAAP EBIT was $311 million versus $222 million
Operating cash flow was $224 million versus $233 million; full-year 2026 operating cash flow now expected to approach $900 million
Company expects third-quarter 2026 adjusted EPS to approach $1.97 and reaffirmed $125 million to $150 million of cost savings
CNO Financial Group reported second quarter 2026 net income of $126 million, or $1.33 per diluted share, up from $91.8 million, or $0.91 per diluted share, a year earlier. The company also raised its full-year 2026 operating earnings per share guidance by 8% at the midpoint, which points to higher expected per-share earnings for shareholders.
Net income was $126 million, or $1.33 per diluted share, versus $91.8 million, or $0.91, in 2Q25.
Net operating income was $120 million, or $1.26 per diluted share, up 45% from $0.87 in 2Q25.
2026 operating EPS guidance raised by 8% at the midpoint from prior guidance.
Repurchased $60.0 million of common stock in 2Q26; authority to repurchase up to an additional $300.4 million remained at June 30, 2026.
Mohawk Industries reported second-quarter 2026 net earnings of $196 million, or $3.22 per diluted share, up from $2.34 a year earlier, on net sales of $3.0 billion, up 6.8%. The results included about $0.63 per share from tariff refunds that were not in the company's second-quarter guidance, and the company expects third-quarter adjusted EPS of $2.50 to $2.60, including about $0.12 from additional tariff refunds.
Q2 2026 net earnings were $196 million and diluted EPS was $3.22, versus $147 million and $2.34 in Q2 2025; adjusted diluted EPS was $3.67 versus $2.77.
Q2 net sales were $3.0 billion, up 6.8% as reported and up 5.0% adjusted for constant days and exchange rates.
Q3 2026 adjusted EPS is expected to be $2.50 to $2.60, or $2.38 to $2.48 excluding tariff refunds and one-time charges.
Paul De Cock will succeed Jeff Lorberbaum as CEO effective September 30, 2026, as previously announced on June 11, 2026.
AXT reported second-quarter 2026 revenue of $47.6 million, up from $26.9 million in the first quarter and $18.0 million a year earlier. GAAP net income attributable to AXT was $11.1 million, or $0.17 per diluted share, compared with a net loss of $7.0 million a year earlier, and the company's CEO cited its highest quarterly indium phosphide revenue to date. The filing gives no forward guidance, so shareholders have the reported quarter and the company's qualitative outlook to weigh.
Revenue was $47.6 million for Q2 2026, compared with $26.9 million in Q1 2026 and $18.0 million in Q2 2025.
GAAP gross margin was 44.9% in Q2 2026, compared with 29.6% in Q1 2026 and 8.0% in Q2 2025.
GAAP net income attributable to AXT was $11.1 million, or $0.17 diluted per share, versus a net loss of $7.0 million, or $0.16 per share, in Q2 2025.
Non-GAAP net income was $11.9 million, or $0.19 per share, excluding stock-based compensation.
Merit Medical reported second-quarter 2026 revenue of $418.8 million, up 10% from a year earlier, and GAAP diluted EPS of $0.65, up from $0.54. The company raised its full-year 2026 revenue guidance to $1.631 billion to $1.643 billion and its non-GAAP EPS guidance to $4.25 to $4.35, both above its April 30, 2026 outlook. Year-to-date operating cash flow and free cash flow both declined, at $110.0 million (down 11%) and $76.6 million (down 14%).
Q2 2026 reported revenue $418.8 million, up 10%; constant currency organic revenue up 9%
GAAP EPS $0.65 vs. $0.54 a year earlier; non-GAAP EPS $1.19, up 18%
2026 revenue guidance raised to $1.631-$1.643 billion; non-GAAP EPS guidance raised to $4.25-$4.35 from $4.01-$4.15
Year-to-date cash flow from operations $110.0 million, down 11%; free cash flow $76.6 million, down 14%
AMH reported second-quarter 2026 rents and other single-family property revenues of $470.1 million, up 2.8% from a year earlier, and net income attributable to common shareholders of $113.6 million, or $0.31 per diluted share, compared with $0.28 a year earlier. The company raised its full-year 2026 Core FFO per share guidance to $1.93-$1.97 from $1.89-$1.95, a change that matters to shareholders because Core FFO is the per-share earnings measure REIT investors commonly track.
Q2 2026 rents and other single-family property revenues rose 2.8% year over year to $470.1 million.
Net income attributable to common shareholders was $113.6 million, or $0.31 per diluted share, versus $0.28 in Q2 2025.
Core FFO attributable to common share and unit holders was $0.49 per share, up 5.2% from the prior year period.
Full-year 2026 Core FFO guidance raised to $1.93-$1.97 from $1.89-$1.95; the midpoint rose $0.03 to $1.95.
SPX Technologies reported second-quarter 2026 revenue of $679.0 million, up 22.9%, and GAAP EPS of $1.56, up 41.8% from a year earlier. The company raised its full-year 2026 guidance for revenue, adjusted EBITDA and adjusted EPS, citing data center demand and the Neptronic acquisition. Total debt rose to $614.7 million and cash fell to $168.2 million, so shareholders will also watch the balance sheet after the July 2026 borrowings for Neptronic.
Q2 2026 revenue of $679.0 million, up 22.9%; GAAP EPS of $1.56, up 41.8%; adjusted EPS of $2.02, up 22.4%
2026 revenue guidance raised to $2.705 to $2.765 billion from $2.575 to $2.645 billion
2026 adjusted EBITDA guidance raised to $630 to $660 million from $600 to $625 million; adjusted EPS guidance raised to $8.20 to $8.60 from $7.75 to $8.15
Total debt was $614.7 million and cash was $168.2 million at June 27, 2026; the company borrowed $340.0 million in July 2026 to fund the Neptronic acquisition
The Bancorp, Inc. reported second quarter 2026 net income of $60.7 million, or $1.45 per diluted share, up from $1.27 a year earlier. The company raised its full-year 2026 EPS guidance to $5.95-$6.05 and maintained its 2027 EPS guidance of $8.10-$8.30. Net interest margin and return on assets declined from a year ago, and fintech loan balances fell sharply from the prior quarter.
Q2 2026 diluted EPS of $1.45 versus $1.27 in Q2 2025, up 14.2%; net income $60.7 million versus $59.8 million
Full-year 2026 EPS guidance raised to $5.95-$6.05, including $1.65-$1.75 in the fourth quarter
2027 EPS guidance maintained at $8.10-$8.30
Ending fintech loans fell to $901.5 million from $1.65 billion at March 31, 2026, which the company attributed to a change in payment processing timing
Schneider National reported second-quarter 2026 operating revenues of $1.6 billion, up 10% from $1.4 billion a year earlier, and income from operations of $71.4 million, up 30%. The company raised its full-year 2026 adjusted diluted earnings per share guidance to $0.90-$1.10 from $0.70-$1.00, a signal of expected earnings growth for shareholders.
Operating revenues rose 10% to $1,568.7 million in the quarter, compared with $1,420.5 million in the second quarter of 2025.
Diluted EPS was $0.28 versus $0.20 a year earlier; adjusted diluted EPS was $0.29 versus $0.21.
Full-year 2026 adjusted diluted EPS guidance was raised to $0.90-$1.10 from $0.70-$1.00.
Full-year 2026 net capital expenditures guidance was lowered to $350-$400 million from $400-$450 million; second-quarter free cash flow was $87.9 million versus $123.0 million a year earlier.
DiamondRock Hospitality reported second quarter 2026 net income attributable to common stockholders of $90.5 million, or $0.44 per diluted share, compared with $38.4 million, or $0.18 per diluted share, a year earlier, and raised its full-year 2026 guidance. The Board also declared a third quarter dividend of $0.11 per share, up 22% from the prior $0.09, which the filing says is supported by the company's second quarter results and outlook. Second quarter results include a one-time benefit of approximately $6.9 million from a Chicago property tax settlement, and the filing states Adjusted FFO per diluted share was $0.41 excluding that benefit.
Q2 2026 net income attributable to common stockholders was $90.5 million, or $0.44 per diluted share, versus $38.4 million, or $0.18 per diluted share, in Q2 2025.
Full-year 2026 Adjusted FFO per share guidance raised to $1.18 to $1.23 from $1.10 to $1.16.
Full-year 2026 Adjusted EBITDA guidance raised to $310.0 million to $320.0 million from $290.2 million to $302.2 million.
Quarterly dividend of $0.11 per share declared July 30, 2026, payable October 14, 2026, to holders of record as of September 30, 2026.
Illumina reported second-quarter 2026 revenue of $1.16 billion, up 9.5% from a year earlier, and non-GAAP diluted EPS of $1.31, up from $1.19. GAAP diluted EPS fell to $1.35 from $1.49, and the company raised its fiscal 2026 revenue and non-GAAP EPS guidance. For shareholders, the higher outlook is the key development, though GAAP earnings declined year over year.
Q2 2026 revenue was $1.16 billion, up 9.5% from Q2 2025; non-GAAP diluted EPS was $1.31 versus $1.19, while GAAP diluted EPS was $1.35 versus $1.49
Fiscal 2026 total revenue guidance raised to $4.60-$4.64 billion from $4.52-$4.62 billion
Fiscal 2026 non-GAAP diluted EPS guidance raised to $5.30-$5.40 from $5.15-$5.30; non-GAAP operating margin guidance unchanged at 23.4%-23.6%
Free cash flow was $162 million for Q2 2026, compared with $204 million a year earlier
LPL Financial reported second-quarter 2026 net income of $379 million, or $4.74 per diluted share, up from $273 million and $3.40 a year earlier. Adjusted EPS rose 29% to $5.84, and the company lowered its 2026 Core G&A outlook to $2,140-2,165 million, which includes Commonwealth-related expenses. The company also resumed share repurchases, with $309 million bought back in the quarter.
Net income $379 million and diluted EPS $4.74 for the quarter ended June 30, 2026, versus $273 million and $3.40 in Q2 2025 and $356 million and $4.43 in Q1 2026
Total revenue $5.19 billion, up 35% year-over-year; gross profit up 24% to $1,618 million
2026 Core G&A outlook lowered to $2,140-2,165 million, including Commonwealth-related expenses
Share repurchases of $309 million in Q2; Board approved a $2.5 billion increase to the repurchase authorization on July 23, 2026; $0.30 per share dividend payable August 28, 2026
Cohu reported second-quarter fiscal 2026 net sales of $149.0 million, up 38% from $107.7 million a year earlier, and a GAAP net loss of $0.2 million, or $0.00 per share, versus a $16.9 million loss a year ago. The company guided third-quarter sales to $170 million plus or minus $7 million and raised its FY26 high-performance computing revenue estimate to $100 million to $110 million.
Q2 net sales $149.0 million, up 38% year over year; GAAP gross margin 45.4%
Q2 non-GAAP net income $14.1 million, or $0.26 per share; GAAP net loss $0.2 million
Third-quarter 2026 sales expected at $170 million +/- $7 million
FY26 high-performance computing revenue estimate raised to $100 million to $110 million
Nextpower reported first-quarter fiscal 2027 revenue of $935 million, up from $864 million a year earlier, and GAAP diluted EPS of $1.07, up from $1.04. It also raised the low end of several fiscal 2027 ranges, including revenue and GAAP diluted EPS, while noting about $50 million of planned costs tied to entering the power conversion market.
Q1 FY27 revenue was $935 million versus $864 million in Q1 FY26; GAAP net income was $165 million versus $157 million.
Adjusted diluted EPS was $1.20 versus $1.16 a year earlier; adjusted EBITDA was $233 million versus $215 million.
FY2027 revenue outlook is $4.1 to $4.4 billion, up from $4.0 to $4.4 billion; GAAP diluted EPS outlook is $3.42 to $3.64, up from $3.22 to $3.64.
The updated outlook includes planned incremental costs of about $50 million related to accelerating entry into the power conversion market.
Amazon reported second quarter 2026 net sales of $200.6 billion, up 20% from a year earlier, and operating income of $27.5 billion, up 43%. Net income was $62.6 billion, or $5.75 per diluted share, helped by $53.4 billion of non-operating other income, primarily from its Anthropic investments, while trailing twelve-month free cash flow turned to an outflow of $7.6 billion as investment in artificial intelligence rose.
Q2 2026 net sales were $200.6 billion, up 20% from $167.7 billion in Q2 2025; AWS segment sales rose 37% to $42.2 billion.
Operating income was $27.5 billion versus $19.2 billion in Q2 2025; AWS operating income was $16.6 billion versus $10.2 billion.
Net income was $62.6 billion, or $5.75 per diluted share, versus $1.68 a year earlier, including $53.4 billion of non-operating other income.
Third quarter 2026 guidance calls for net sales of $197.0 billion to $202.0 billion and operating income of $22.5 billion to $26.5 billion, compared with $17.4 billion in Q3 2025.
Etsy completed its sale of Depop to eBay on July 30, 2026, receiving approximately $1.4 billion in cash, which includes a $1.2 billion purchase price plus $200 million of net adjustments and interest. Etsy plans to use the proceeds for general corporate purposes, including the accelerated share repurchase program outlined in its April 29 Shareholder Letter. The net proceeds remain subject to post-closing adjustments, and the actual gain on sale may differ materially from the $805.0 million pro forma estimate.
Closing date: July 30, 2026. Aggregate cash consideration is about $1.4 billion: $1.2 billion purchase price plus $200 million of net purchase price adjustments and interest.
Net cash proceeds remain subject to post-closing adjustments under the Purchase Agreement.
Pro forma balance sheet as of March 31, 2026 shows a gain on sale of $805.0 million; Etsy says the actual gain will be based on Depop's carrying value at closing and may differ materially.
Etsy plans to use proceeds for general corporate purposes, including accelerating its share repurchase program. A Second Amendment to the credit agreement with JPMorgan Chase Bank, N.A. dated July 30, 2026 is filed as Exhibit 10.1.
Agree Realty reported second-quarter 2026 results on July 30, 2026, with net income attributable to common stockholders up 11.5% to $52.8 million and AFFO per share up 7.4% to $1.14. The company raised its 2026 AFFO per share guidance to $4.57 to $4.59 and its investment volume guidance to $1.6 billion to $1.8 billion, citing a Company-record $502 million invested in the quarter. For shareholders, the filing shows higher per-share cash earnings and a larger expected investment program for the year.
Q2 2026 net income attributable to common stockholders rose 11.5% to $52.8 million; net income per share rose 2.2% to $0.44
Core FFO per share rose 7.5% to $1.13; AFFO per share rose 7.4% to $1.14
2026 AFFO per share guidance raised to $4.57 to $4.59 from $4.54 to $4.58
2026 investment volume guidance raised to $1.6 billion to $1.8 billion from $1.4 billion to $1.6 billion
PTC Therapeutics reported second-quarter 2026 total revenue of $360.5 million, up from $178.9 million a year earlier, and net income of $83.5 million, compared with a net loss of $64.8 million in the prior-year quarter. The company raised its 2026 product revenue guidance to $850 million to $950 million and its total revenue guidance to $1.18 billion to $1.28 billion, and it also appointed Hege Sollie-Zetlmayer, its former Chief Human Resources Officer, to the board.
Q2 2026 total revenue was $360.5 million, including $238.8 million of net product revenue and a $50.0 million Novartis milestone recorded as collaboration revenue.
Full-year 2026 product revenue guidance was raised to $850 million to $950 million from $750 million to $850 million.
Sephience generated $151.3 million in Q2 2026 net product revenue; cash, cash equivalents and marketable securities were $2.2 billion as of June 30, 2026.
Hege Sollie-Zetlmayer was appointed to the board effective July 28, 2026, filling a vacancy.
Exponent reported second-quarter 2026 results for the quarter ended July 3, 2026, with total revenues up 21% to $171.6 million and net income up to $29.4 million, or $0.60 per diluted share, from $0.52 a year earlier. The company raised its full-year 2026 revenue growth and EBITDA margin guidance and declared a $0.31 quarterly dividend and an additional $50 million share repurchase authorization.
Q2 revenues before reimbursements rose 12% to $148.9 million; net income was $29.4 million, or $0.60 per diluted share, versus $26.6 million, or $0.52, in Q2 2025.
Full-year 2026 guidance raised: revenues before reimbursements to grow 9% to 10%, and EBITDA to be 27.8% to 28.1% of revenues before reimbursements.
Third-quarter 2026 outlook: revenues before reimbursements expected to grow 8% to 10%, with EBITDA at 28.0% to 28.5% of revenues before reimbursements.
Quarterly dividend of $0.31 per share is payable September 18, 2026, to holders of record as of September 4, 2026; the buyback authorization was increased by $50 million.
Columbia Sportswear reported second-quarter 2026 net sales up 2% to $614.4 million and diluted earnings of $0.52 per share, compared with a loss of $0.19 a year earlier. The results include a $0.93 per share benefit from a recovery of IEEPA tariffs, and the company raised its full-year 2026 diluted EPS outlook to $4.45 to $4.90 from $3.55 to $4.00. Management said its second-half outlook has moderated, and third-quarter net sales are expected to be $929 million to $943 million, down 1.5% to flat.
Q2 net sales were $614.4 million, up 2% (1% in constant currency), while U.S. net sales fell 4% to $320.1 million.
Q2 operating income was $30.9 million, compared with an operating loss of $23.6 million a year earlier.
Full-year 2026 diluted EPS outlook raised to $4.45 to $4.90 from $3.55 to $4.00; net sales outlook unchanged at $3.43 to $3.50 billion.
Board declared a quarterly dividend of $0.30 per share, payable September 3, 2026, to holders of record on August 20, 2026.
Cerus reported second-quarter 2026 total revenue of $63.3 million, up 5% from $60.1 million a year earlier, with product revenue up 10% to $57.4 million. The company narrowed its full-year 2026 product revenue guidance by raising the low end to $229 million to $231 million, and its net loss narrowed to $2.9 million, or $0.01 per share, from $5.7 million, or $0.03 per share, a year earlier.
Q2 2026 total revenue $63.3 million vs. $60.1 million in Q2 2025; product revenue $57.4 million, up 10%
Q2 2026 net loss attributable to Cerus $2.9 million ($0.01 per share) vs. $5.7 million ($0.03 per share) in Q2 2025
Product gross margin 51.4% vs. 55.2% a year earlier; company cites weaker U.S. dollar versus the Euro and higher product costs
2026 product revenue guidance now $229 million to $231 million, up from $227 million to $231 million; IFC guidance raised to $23 million to $25 million
Dexcom reported second-quarter 2026 revenue of $1.308 billion, up 13% from a year earlier, and GAAP diluted earnings of $0.64 per share, up from $0.45. The company raised the midpoint of its fiscal 2026 revenue guidance to $5.18 billion to $5.25 billion and increased its margin guidance, which points to stronger results for shareholders than previously expected.
Q2 2026 revenue was $1.308 billion, up from $1.157 billion, with U.S. revenue up 11% and international revenue up 19%.
GAAP net income was $249.1 million, or $0.64 per diluted share, versus $179.8 million, or $0.45, a year earlier.
Fiscal 2026 revenue guidance is $5.18 billion to $5.25 billion, representing about 11% to 13% growth.
Cash, cash equivalents and marketable securities totaled $1.95 billion as of June 30, 2026.
CareDx reported second-quarter 2026 revenue of $132 million, up 52% from a year earlier, and GAAP net income of $111 million, which includes a $113 million gain on the sale of its Lab Products business. The company raised its full-year 2026 revenue guidance to $490 million to $500 million and its adjusted EBITDA guidance to $66 million to $78 million.
Revenue of $132 million versus $87 million in Q2 2025; Testing Services revenue rose 61% to $100 million.
GAAP diluted net income per share was $2.07, versus a loss of $0.16; non-GAAP diluted net income per share was $0.37, versus $0.10.
Adjusted EBITDA was $25 million versus $5 million in Q2 2025.
2026 guidance raised: revenue to $490 million to $500 million (from $447 million to $465 million) and adjusted EBITDA to $66 million to $78 million (from $43 million to $57 million).
Neurocrine Biosciences reported second-quarter 2026 revenue of $959 million, up 39% from $688 million a year earlier, with GAAP diluted earnings per share of $1.39 versus $1.06. The company raised its full-year 2026 INGREZZA net sales guidance to $2.825 billion to $2.875 billion from $2.7 billion to $2.8 billion, and it completed its Soleno Therapeutics acquisition in May 2026.
Total revenue was $959 million in Q2 2026 versus $688 million in Q2 2025.
GAAP net income was $144 million, or $1.39 per diluted share, versus $108 million, or $1.06, a year earlier.
INGREZZA full-year 2026 net product sales guidance was raised to $2.825 billion to $2.875 billion from $2.7 billion to $2.8 billion.
VYKAT XR net product sales were $54 million from May 18, 2026, the Soleno acquisition closing date.
Alignment Healthcare reported second-quarter 2026 total revenue of $1,335.6 million, up 31.6% year-over-year, and net income of $36.6 million, compared with $15.7 million a year earlier. The company raised the midpoint of all its full-year 2026 guidance metrics, including membership, revenue, adjusted gross profit and adjusted EBITDA.
Q2 2026 total revenue was $1,335.6 million, up 31.6% year-over-year; health plan membership was about 294,100, up 31.5%.
Net income was $36.6 million versus $15.7 million; diluted EPS was $0.17 versus $0.07 a year earlier.
Adjusted EBITDA was $68.1 million, a 5.1% margin and up 48.4% year-over-year.
Full-year 2026 guidance: revenue $5,195 million to $5,225 million; adjusted EBITDA $145 million to $163 million.
Tempus AI reported second quarter 2026 revenue of $382.5 million, up 22% year-over-year, and GAAP net income of $5.6 million, compared with a net loss of $42.8 million a year earlier. The company raised its full-year 2026 revenue guidance to $1.595 to $1.605 billion, while keeping its 2026 Adjusted EBITDA expectation at about $65 million.
Q2 2026 revenue was $382.5 million, up 22% year-over-year; Diagnostics rose 20% and Data and Applications rose 28%.
GAAP net income was $5.6 million, including $98.5 million in unrealized gains on marketable securities; Q2 2025 was a net loss of $42.8 million.
Adjusted EBITDA was $8.0 million, compared with ($5.6 million) in Q2 2025.
Full-year 2026 revenue guidance raised to $1.595 to $1.605 billion; Adjusted EBITDA guidance of about $65 million unchanged. Guidance excludes the pending Personalis acquisition at $16.25 per share.
Monolithic Power Systems reported record second-quarter 2026 revenue of $980.6 million, up 21.9% from the first quarter and 47.6% from a year earlier, with GAAP net income of $257.3 million, or $5.22 per diluted share, compared with $2.81 a year earlier. The company forecast third-quarter 2026 revenue of $1,140 million to $1,160 million and said its Board authorized an additional $500 million for stock repurchases, bringing the total authorization to $1 billion.
Q2 2026 revenue of $980.6 million compared with $804.2 million in Q1 2026 and $664.6 million in Q2 2025; Enterprise Data revenue rose 44.8% from Q1 to $380.6 million.
GAAP diluted EPS of $5.22 for Q2 2026 vs. $3.92 in Q1 2026 and $2.81 in Q2 2025; non-GAAP diluted EPS was $6.50.
Q3 2026 outlook: revenue of $1,140 million to $1,160 million and GAAP gross margin of 55.2% to 55.8%.
Board authorized an additional $500 million for stock repurchases, bringing total current authorization to $1 billion.
TriMas reported second quarter 2026 net sales of $174.6 million, up 1.6% from a year earlier, and adjusted diluted EPS from continuing operations of $0.52, up from $0.20. The company raised the low end and midpoint of its full-year 2026 adjusted diluted EPS outlook to $1.60 to $1.70, from $1.50 to $1.70. GAAP diluted EPS of $1.86 includes a $53.9 million non-cash deferred tax impact tied to the TriMas Aerospace divestiture.
Q2 2026 net sales $174.6 million, up 1.6%; adjusted operating profit $14.9 million, up 29.1%
Full-year 2026 adjusted diluted EPS outlook now $1.60 to $1.70, versus $1.50 to $1.70 previously
Repurchased 509,264 shares for $18.9 million in Q2; $76.5 million remained under the authorization at June 30, 2026
Cash and cash equivalents of $1.24 billion at June 30, 2026; Q2 free cash flow use of $12.9 million
EMCOR reported record second-quarter 2026 revenue of $5.15 billion, up 19.8%, and diluted EPS of $9.06, up 34.8% from a year earlier. The company raised its full-year 2026 revenue guidance to $20.00 billion-$20.50 billion and its diluted EPS guidance to $32.00-$33.25, reflecting stronger results and visibility into the rest of the year.
Q2 2026 operating income was $547.3 million, or 10.6% of revenues, versus $415.2 million (9.6%) a year earlier.
Remaining performance obligations reached a record $17.14 billion at June 30, 2026, up 43.9% year-over-year.
2026 diluted EPS guidance raised to $32.00-$33.25 from $28.25-$29.75; operating margin guidance raised to 9.5%-9.8% from 9.0%-9.4%.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.